OKYO Pharma filed an Investigational New Drug application with the U.S. Food and Drug Administration for the development of OK-101 to treat Neuropathic Corneal Pain Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. NCP remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the opportunity to establish OK-101’s potential to treat this condition. The open-label trial will provide an opportunity to evaluate the safety and efficacy of OK-101 for NCP in a real-world clinical setting, fostering a better understanding of its potential benefits for patients. The NCP trial will be led by Pedram Hamrah, MD, Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist, Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is a member of OKYO‘s Scientific Advisory Board and plans to serve as Principal Investigator of the study, which will be conducted at Tufts Medical Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OKYO:
- OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
- OKYO Pharma announces safety data profile for OK-101 Phase 2 trial of DED
- OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
- OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
- OKYO Pharma prices $4.0M registered direct offering at $1.50 per share